Resources

Samuel Engel discusses Merck's VERTIS clinical trial program and recent ertugliflozin research including the VERTIS SITA study and the VERTIS MET study,

In this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of studies related to ertugliflozin.

In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.

In part 2 of this Exclusive Interview, Dr. Samuel Engel explains the effects of ertugliflozin on typical biometrics in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the cardiovascular study portion of the ertugliflozin trial.

In part 4 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about looking at the impact of DPP-4s on hypoglycemia.

In part 1 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the current progress of INGAP and the challenges yet to be overcome.

In this week's Homerun Slides, we conclude our 12-part series with pharmacologic approaches to treating chronic kidney disease in type 2.

Future directions and potential application of metabolite profiling in type 2 diabetes: metabolomics approaches have unmasked a variety of metabolic pathways influenced by T2DM or insulin resistance, moving the field of metabolic physiology beyond a “glucocentric” viewpoint of these conditions. However, a difficulty in interpretation is that the fasting concentration of a metabolite only reflects a single moment in time, and etiology or tissue origins of any metabolite differences across comparator groups requires further validation.

Diabetes has long been divided into type 1 and type 2. But a third type has entered the mix — and we aren't diagnosing it correctly.